ZURICH: Swiss drugmaker Roche said it had agreed to buy privately held Bina Technologies for an undisclosed price.
The deal comes on a day when Roche suffered a double blow, as two clinical studies of drugs for breast cancer and Alzheimer’s disease failed, sparking the biggest percentage fall in its stock in five years.
On Thursday, Roche agreed to pay up to $489 million to acquire Austrian biotech company Dutalys, a specialist in the discovery and development of so-called bi specific antibodies.
California based Bina Technologies provides technology for the processing and management of genomic information.
